Clinical Trials Browser

Phase 2 × Has results × 3-Iodobenzylguanidine × Clear all

NCT04385277 2025-10-27

Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL)

Phase 2 Active not recruiting

41 enrolled 13 charts

Neuroblastoma, Ganglioneuroblastoma

NCT00253435 2023-04-10

N2001-02: I-MIBG With Intensive Chemotherapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma

Phase 2 Completed

50 enrolled 12 charts

Neuroblastoma

NCT02035137 2022-06-08

N2011-01

Phase 2 Completed

114 enrolled 13 charts

Neuroblastoma

NCT00874614 2020-02-20

A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma

Phase 2 Unknown

74 enrolled 10 charts 1 FDA

CNSEndocrineNET

Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors

NCT01413503 2018-09-18

A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors

Phase 2 Completed

50 enrolled 7 charts

Neoplasms, Paraganglioma, Pheochromocytoma, Recurrence